Epigenetic dysregulation — heritable, non-mutational alterations in gene transcription and expression governed by chromatin-modifying processes such as histone acetylation — is theorized to be a central, disease-defining vulnerability in T-cell lymphomas, distinguishing them from other malignancies that do not show comparable sensitivity to epigenetic-targeted agents. Histone deacetylase (HDAC) inhibitors constitute a class of drugs that act on this epigenetic machinery, with proposed mechanisms of action including induction of DNA damage, and are being investigated both as single agents and in combination with other epigenetic- or immune-targeted drugs to improve response rate and durability of response. This sits within molecular oncology and cancer epigenetics, at the intersection of chromatin biology and hematologic malignancy therapeutics.
Epigenetic dysregulation — heritable, non-mutational alterations in gene transcription and expression governed by chromatin-modifying processes such as histone acetylation — is theorized to be a cent…